|
S.V. Podachina, E.V. Biryukova, I.V. Solovievа
Combination therapy for type 2 diabetes maintains its position. Clinical case
|
№3 / 2023
|
|
E.Yu. Smirnova
Glycemic variability diary as a tool for assessing the effectiveness of diabetes therapy. Clear and accessible. Case series
|
№3 / 2023
|
|
E.V. Biryukova, M.V. Shinkin, I.A. Morozovа
Modern practice of lipid-lowering pharmacotherapy: the choice of the optimal fixed combination
|
№3 / 2023
|
|
M.B. Antsiferov, O.M. Koteshkova, O.V. Dukhareva, N.A. Demidov, M.S. Novikova
Place of GLP-1 receptor antagonists and SGLT-2 inhibitors in modern therapy of type 2 diabetes mellitus
|
№11-12 / 2022
|
|
N.A. Petunina, N.S. Martirosyan, F.V. Valeeva
Cardiovascular outcomes during treatment with dipeptidyl peptidase-4 inhibitors depending on renal function and combination with metformin: a systematic review
|
№11-12 / 2022
|
|
M.B. Antsiferov, N.A. Demidov, T.I. Safronova, O.A. Mishra
Efficacy and safety of fixed combination insulin glargine 100 u/ml and lixisenatide in patients with type 2 diabetes mellitus depending on age and baseline HbA1C in the SOLO study
|
№11-12 / 2022
|
|
M.S. Novikova, O.M. Koteshkova, M.B. Antsiferov
Efficacy and safety of ertugliflozin: results of the VERTIS CV sub-study in patients receiving a stable dose of insulin
|
№4 / 2022
|
|
S.S. Apetov, V.V. Apetova
The role of menopausal hormone therapy in the prevention of type 2 diabetes melltus in postmenopausal women
|
№4 / 2022
|
|
A.D. Akulova (1), Yu.S. Zhulina (1), V.V. Rozhkova (1), E.Yu. Martynova (2), Yu.E. Poteshkin (1)
Problem of treatment adherence in patients with type 2 diabetes mellitus
|
№4 / 2022
|
|
N.S. Alekseeva
Carbohydrate metabolism disorders and osteoporosis
|
№12 / 2021
|
|
A.F. Verbovoy, Yu.A. Dolgikh, N.I. Verbovaya, T.V. Lomonova
Obesity: an invisible disease
|
№12 / 2021
|
|
P.B. Shorokhova, V.L. Baranov
Differentiated approach to metformin therapy in newly diagnosed type 2 diabetes mellitus from the perspective of pharmacogenetics
|
№12 / 2021
|
Русский
